|
|
|
Volumn 6, Issue 6, 2000, Pages 2126-2128
|
|
Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
EPIDERMAL GROWTH FACTOR RECEPTOR;
LIAROZOLE;
RETINOIC ACID;
RETINOIC ACID BINDING PROTEIN;
RETINOIC ACID RECEPTOR;
TRANSFORMING GROWTH FACTOR ALPHA;
BIOPSY;
CANCER CHEMOTHERAPY;
CANCER PREVENTION;
CLINICAL TRIAL;
DISEASE MARKER;
DRUG RESPONSE;
EDITORIAL;
HEAD AND NECK CARCINOMA;
HUMAN;
LUNG NON SMALL CELL CANCER;
MOUTH MUCOSA;
NONHUMAN;
PRIORITY JOURNAL;
SQUAMOUS CELL CARCINOMA;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS, HORMONAL;
BIOLOGICAL MARKERS;
BIOPSY;
CLINICAL TRIALS;
HEALTH SERVICES RESEARCH;
HUMANS;
IMIDAZOLES;
MOUTH;
MUCOUS MEMBRANE;
NEOPLASMS;
TREATMENT OUTCOME;
TRETINOIN;
|
|
EID: 0034042949
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (3)
|
|
References (22)
|
